Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Guardant Health Inc Company Overview 4

Guardant Health Inc Company Snapshot 4

Guardant Health Inc Pipeline Products and Ongoing Clinical Trials Overview 4

Guardant Health Inc – Pipeline Analysis Overview 7

Guardant Health Inc - Key Facts 7

Guardant Health Inc - Major Products and Services 8

Guardant Health Inc Pipeline Products by Development Stage 9

Guardant Health Inc Ongoing Clinical Trials by Trial Status 11

Guardant Health Inc Pipeline Products Overview 13

Anti-RSP03 Antibody Based Blood Test 13

Anti-RSP03 Antibody Based Blood Test Product Overview 13

Gene-Based Test - Lung Cancer 14

Gene-Based Test - Lung Cancer Product Overview 14

GUARDANT360 15

GUARDANT360 Product Overview 15

GUARDANT360 Clinical Trial 16

Guardant360 CDx Test - Tepotinib 18

Guardant360 CDx Test - Tepotinib Product Overview 18

Guardant360 Companion Diagnostic Assay - Glesatinib 19

Guardant360 Companion Diagnostic Assay - Glesatinib Product Overview 19

Guardant Health Inc - Key Competitors 20

Guardant Health Inc - Key Employees 21

Guardant Health Inc - Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Guardant Health Inc, Recent Developments 23

Jul 19, 2018: New Nature Medicine Study Demonstrates Ability of The Guardant360 Assay to Predict Patient Response to Immunotherapy in Advanced Gastric Cancer Patients 23

Jul 18, 2018: Foundation Medicine and Guardant Health Agree to Settle Patent Infringement Lawsuit 23

Jul 12, 2018: Guardant Health Appoints Leena Das-Young to Lead Efforts to Develop Liquid Biopsy Products for Early-Stage Cancer Applications 23

Jul 12, 2018: Guardant Health Announces Medicare Coverage for the Guardant360 Assay in Non-Small Cell Lung Cancer 24

May 23, 2018: Guardant Health to Present 29 Abstracts at ASCO Advancing the Science of Liquid Biopsy Across Multiple Indications and Applications 24

Apr 26, 2018: Guardant Health Publishes Extensive Validation of Guardant360 Assay Comprising Largest-Published Blood-Tissue Comparison 25

Apr 13, 2018: Guardant Health to Present Validation Data for the GuardantOMNI assay 25

Mar 19, 2018: Guardant Health Applauds Medicare For Final Decision Benefiting Advanced Cancer Patients 26

Mar 13, 2018: SCRUM-Japan GI-SCREEN Aims for Realizing of Cancer Precision Medicine Utilizing Liquid Biopsy by Analyzing Comprehensive Cancer Genome Alterations in Blood 26

Mar 12, 2018: Guardant Health and National Cancer Center East Japan Announce Liquid Biopsy Arm of Lung Cancer Trial 27

Appendix 28

Methodology 28

About GlobalData 31

Contact Us 31

Disclaimer 31

Summary

Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection used during cancer treatment for residual disease monitoring and recurrence monitoring. Guardant Health also develops a cloud-based information platform for liquid biopsy-based genomic testing in cancer treatments. The company provides somatic alterations across all solid tumor sites. Guardant Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Guardant Health Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company